$170 Million is the total value of Casdin Capital, LLC's 29 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BOLD | New | AUDENTES THERAPEUTICS INC | $4,430,000 | – | 260,000 | +100.0% | 2.61% | – |
SGMO | New | SANGAMO THERAPEUTICS INC | $4,420,000 | – | 850,000 | +100.0% | 2.61% | – |
PACB | New | PACIFIC BIOSCIENCES CALIF IN | $3,619,000 | – | 700,000 | +100.0% | 2.14% | – |
CDXS | New | CODEXIS INC | $3,240,000 | – | 675,000 | +100.0% | 1.91% | – |
JNCE | New | JOUNCE THERAPEUTICS INC | $2,859,000 | – | 130,000 | +100.0% | 1.69% | – |
TSRO | New | TESARO INC | $2,693,000 | – | 17,500 | +100.0% | 1.59% | – |
CLVS | New | CLOVIS ONCOLOGY INC | $1,464,000 | – | 23,000 | +100.0% | 0.86% | – |
ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $1,134,000 | – | 420,000 | +100.0% | 0.67% | – |
CRIS | New | CURIS INC | $639,000 | – | 230,000 | +100.0% | 0.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
CODEXIS INC | 22 | Q3 2023 | 8.1% |
SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-31 |
4 | 2024-05-28 |
4 | 2024-05-28 |
4 | 2024-05-22 |
SC 13D/A | 2024-05-22 |
4 | 2024-05-17 |
13F-HR | 2024-05-15 |
4 | 2024-05-15 |
4 | 2024-05-02 |
SC 13G | 2024-04-18 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.